Log weekly study shots
Record the date of each weekly study injection and keep a simple timeline of your trial routine. Use only the dose information provided by your study team.
Retatrutide Clinical Trial Tracker
Track retatrutide during your clinical trial
Publicado por Shotsy · Última atualização: agosto de 2026
Retatrutide is an investigational medication and is not FDA approved. If you are a clinical trial participant taking weekly study injections, Shotsy can help you record shots, side effects, weight, and notes for conversations with your study team.
Start Tracking Retatrutide
Resposta rápida
Retatrutide is not FDA approved. It is an investigational medication being studied in clinical trials, where some participants are taking weekly retatrutide shots. Shotsy is a tracking tool for trial participants who want to record shot dates, reported study dose, side effects, weight, and notes. Shotsy does not provide retatrutide, dosing advice, or clinical trial enrollment.
Why clinical trial participants track
Study visits depend on reliable notes
Record each study injection date, the dose reported by your study team, and questions to bring to your next trial visit. A clear timeline can make conversations with the research team easier.
Side effects can be hard to remember
Log nausea, appetite changes, bowel symptoms, fatigue, injection-site reactions, and other observations when they happen. Your study team, not the app, should interpret symptoms and decide what they mean.
Weight changes need context
Weight is only one study measurement. Tracking weight beside shot dates, symptoms, meals, hydration, and notes helps you keep your own record without treating the app as a clinical trial data system.
Retatrutide is not an approved medicine
Retatrutide remains investigational and is not FDA approved. This page does not explain how to obtain it outside a clinical trial, and Shotsy cannot replace trial instructions, study visits, or investigator guidance.
How Shotsy can support a retatrutide trial routine
Track side effects with notes
Rate symptoms and add context about when they began, how long they lasted, and whether they affected daily activities. Contact your study team using the trial process for medical questions.
See weight trends
Chart weight over time and compare it with your own shot log. A chart is for personal organization and is not a substitute for the measurements or endpoints collected by the clinical trial.
Keep questions in one place
Use notes to prepare questions about symptoms, study visits, procedures, or the trial schedule. Do not use the app to change a study dose or skip a required visit.
Keep your approved medication history
Shotsy can also track approved GLP-1 medications in a separate history if your clinician changes your treatment. Follow the clinical trial team and your prescriber when managing any medication transition.
Export a personal record
Use Shotsy exports to organize your personal notes for a conversation with your study team. The export is not an official case report form and does not replace trial documentation.
What GLP-1 users say about Shotsy
Traduzido de avaliações textuais em inglês publicadas na App Store dos Estados Unidos.
★★★★★
Extremamente útil!
“É uma forma super útil e extremamente detalhada de acompanhar seu progresso enquanto você usa um GLP-1. Acho fascinante correlacionar o nível estimado de medicação no meu corpo com o que posso estar sentindo, e é interessante ver o gráfico do meu progresso! Recomendo muito!”
★★★★★
Fácil de usar e útil
“Além de acompanhar minhas proteínas, macros, hidratação, peso etc., eu estava hesitante em ter mais um app de acompanhamento. Mas achei muito difícil acompanhar todas as doses dos meus medicamentos, não apenas GLP-1, sem ele. Este app é fácil de usar e tem espaço para todos os dados necessários. Vou continuar usando-o durante toda esta jornada. Recomendo muito!”
Retatrutide status and trial context
Retatrutide, also known as LY3437943, is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors. It has not been approved by the FDA or any other regulatory agency. Lilly is studying it in clinical trials, including the TRIUMPH program. Participants should follow their study team instructions for every dose, visit, measurement, and safety report.
A 2023 phase 2 trial studied once-weekly retatrutide doses of 1 mg, 4 mg, 8 mg, and 12 mg in adults with obesity. Those were study doses in that protocol, not an approved dosing schedule. The publication reported gastrointestinal adverse events and dose-dependent heart-rate changes, which is why trial participants should report symptoms through the study process.
Reported trial doses, not an approved schedule
The rows below summarize dose groups reported in the phase 2 obesity publication. They are included for participant record organization only. They are not recommendations, do not describe how to obtain retatrutide, and must not override your trial protocol.
| Dose | Fase | Duração típica |
|---|---|---|
| 1 mg | Phase 2 study group | Protocol-defined |
| 4 mg | Phase 2 study group | Protocol-defined |
| 8 mg | Phase 2 study group | Protocol-defined |
| 12 mg | Phase 2 study group | Protocol-defined |
Retatrutide is not FDA approved. Trial participants must follow the dose and schedule supplied by their research team.
Retatrutide tracker: frequently asked questions
Is retatrutide FDA approved?
No. Retatrutide is not FDA approved. Lilly describes it as an investigational medication being evaluated in clinical trials. Shotsy does not provide retatrutide, enroll participants, or give dosing instructions. If you are in a trial, follow the research team instructions and report symptoms through the trial process.
What is retatrutide?
Retatrutide, also called LY3437943, is an investigational medicine designed to activate GIP, GLP-1, and glucagon receptors. Its safety and effectiveness are still being studied. Published trial doses are research protocol details, not an approved prescription schedule.
Can Shotsy track retatrutide shots?
Shotsy can help a clinical trial participant record weekly shot dates, reported study dose, side effects, weight, and notes. It is a personal tracking tool only. It cannot verify the medication, measure drug levels, replace trial records, or tell you what dose to take.
How should clinical trial participants use Shotsy?
Use Shotsy as a personal log alongside the official trial process. Record the information your study team permits you to keep, bring questions to study visits, and report adverse events through the trial contact. Do not use the app to change a dose, skip a visit, or seek retatrutide outside the trial.
Fontes
- What to know about retatrutide, Eli Lilly
- Retatrutide Phase 2 obesity trial, New England Journal of Medicine via PubMed
- TRIUMPH-1 retatrutide clinical trial registration, ClinicalTrials.gov
- TRIUMPH-3 retatrutide clinical trial registration, ClinicalTrials.gov
- Shotsy on the App Store (ratings and customer reviews)
Retatrutide is not FDA approved and remains investigational. Medical and trial facts on this page come from Lilly, ClinicalTrials.gov, and the peer-reviewed publication listed above, verified in agosto 2026. This page does not explain how to obtain retatrutide outside a clinical trial. Follow your study team instructions and consult a healthcare professional for medical questions.
Track your trial routine with care
Shotsy helps organize personal notes about shots, symptoms, weight, and questions. It does not provide retatrutide or medical advice.
Download Shotsy for Free